Answers are grounded in this paper and cite their sources.
Experimental findings reveal that PROM2 acts as a therapeutic target, activating inflammatory pathways that worsen liver fibrosis.
PROM2 contributes to liver fibrosis by promoting EMT and activating NLRP3-dependent inflammatory pathways, suggesting it as a potential therapeutic target for liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: